Novo Nordisk Between Collapse and new Beginning! Can Wegovy Turn the Tide After Further FDA Approval?

Novo Nordisk (NVO) is going through one of its most challenging phases in decades. After a share price drop of 66% and increasing pressure from politics and competition, the former market favorite seemed to be stumbling. However, a surprising approval from U.S. authorities now brings new hope. Wegovy is now allowed to be used for the dangerous liver disease MASH, a step that could be crucial not only for millions of patients but also for the future of the company. The stock is climbing pre-market by more than 7% to over $56. Novo Nordisk in transition...